RE:RE:Maybe new shareholders do need a reminder ...nozzpack wrote: Meir bought a reciprocal deal on the assumption that with all that cash and Goodman's reputation that his investment in GUD would be a profitable .
After several years, it became obvious that Goodman's performance hardly matched his reputation which, projected ahead , was a disaster for Meirs investment.
It so happens that Meir called it spot on.
There is very little in the way of significant drugs in the pipeline and the LATAM investment is only reinforcing Goodman's incompetence.
So expect to see GUD continue to stumble, with share buybacks probably reaching $4.50.
A massive financing will be done at $4 almost all taken by insiders, and ordinary shareholders are left holding the bag.
Then Goodman announces a going private arrangement at $4 ..
Goodman could have done that with Paladin when the price slipped from $10 to $3 (roughly). But he didn't do that. Over the next 12 years it climbed to $45 (roughly). Slowly building a pharma llciencing business that gained momentum.
Not sure why he would announce a PP when he's very proud of offering each one at higher prices. I doubt you'll see the next one at a price under $12 per share - unless we break the bank and due to a time sensitive opportunity, need more cash ASAP. Don't see it happening - but never say never !
Again ... regarding Meir ... he was very eager to go after diamonds - in rugged terrain, with our money. If you know the shareholder base, that wasn't going to happen.
If you want to follow Meir and see how well he does, just follow his deals for Medison Canada - we'll see how long it takes him to build that out as well. It's going to be a long road for him.
\
Right now, we're rivaling his total revenue at Medison and we're 6 years in ... he's been at it for 25 years. You know he was having his issues too as dividends were slipping.
Our problem is different - we need efficency gain at Grupo, we need to amalgamate at various levels and we need to grow the future of specialty drugs in LATAM/ROW. It's a big job but it will come together - with or without us as investors.
IMO.